Canaccord Initiates Illumina Coverage with Buy Rating | GenomeWeb

NEW YORK (GenomeWeb) – Investment bank Canaccord Genuity today started coverage of Illumina with a Buy rating and a $275 price target on the firm's stock. 

Noting the flush next-generation sequencing market and the large shadow cast by Illumina in the space, Canaccord analyst Mark Massaro called Illumina "a must-own stock for large-cap growth … given the company's dominant leadership position, innovation, and pipeline in the dynamic next-generation sequencing market opportunity we peg at close to $50 billion by the end of the decade." 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.

Dec
13
Sponsored by
Agilent Technologies

This webinar will discuss a genomic strategy that detects single nucleotide variants and copy number variants in a single assay.

Dec
15
Sponsored by
PierianDx

This webinar will be an interactive roundtable discussion on established and emerging regulatory, scientific, and medical topics related to next-generation sequencing in the clinical setting.